Cardiovascular Risk Factor, Endothelial Dysfunction, Rheumatoid Arthritis, Stiffness, Aortic
Conditions
Keywords
Methotrexate, Rheumatoid arthritis, Blood pressure, Arterial stiffness, Cardiovascular risk
Brief summary
The investigators will study the effects of methotrexate on blood pressure, arterial stiffness and endothelial function in patients with rheumatoid arthritis.
Detailed description
Patients with rheumatoid arthritis have an increased risk of stroke and heart attack when compared to the rest of the population. Recent studies have shown that methotrexate, a disease-modifying antirheumatic drug (DMARDs) commonly prescribed for rheumatoid arthritis, reduces this risk. However, the mechanisms responsible for the protective effects of methotrexate on the heart and the brain are unknown. The investigators have recently completed an observational study in participants with rheumatoid arthritis treated with either methotrexate or with other DMARDs. Participants on methotrexate had lower blood pressure and 'healthier' blood vessels than participants treated with other DMARDs. These differences were maintained over a period of 8 months. These results suggest that methotrexate lowers blood pressure and exerts salutary effects on blood vessels, which might explain the reduced risk of stroke and heart attack with this drug. However, the observational nature of this study does not allow establishing a clear cause-effect relationship between methotrexate treatment and the observed changes in blood pressure and blood vessels. In order to address this issue, the investigators will recruit participants that have been recently diagnosed with rheumatoid arthritis and are about to start treatment with either methotrexate (Group 1) or another DMARD (Group 2). Then, the investigators will assess their blood pressure and blood vessels for 6 months. The investigators will use an injectable (subcutaneous) form of methotrexate because this might provide better effects on blood pressure and blood vessels. The investigators will also study a third group (Group 3) of rheumatoid arthritis participants already on treatment (\> 1 year) with oral methotrexate, with or without other DMARDs. They will be switched to subcutaneous methotrexate, but continuing all their other medications, for 6 months to see whether the subcutaneous form can further reduce blood pressure and provide additional salutary effects on blood vessels. Finally, the investigators will study a fourth group (Group 4) of participants with rheumatoid arthritis already on treatment (\> 1 year) with DMADRs other than methotrexate who will continue with the same medications for 6 months, to assess possible fluctuations in blood pressure and blood vessel markers over time. Each participant will attend three study visits (baseline, 1 and 6 months), each lasting between 60 and 90 min.
Interventions
DRUGMethotrexate
See arm descriptions
DRUGSulfasalazine
See arm description
DRUGOther DMARDs
See arm
Sponsors
University of South Australia
medac GmbH
Flinders University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with rheumatoid arthritis according to EULAR/ACR 2010 criteria. * Age ≥18 years. * Written informed consent, dated and signed before initiating any study-related procedure.
Exclusion criteria
* Contraindication to MTX or sulfasalazine. * Patient who cannot be followed during 6 months. * Active alcohol or substance abuse within the last 12 months. * Participation in a clinical trial within 3 months prior to the start of the study. * Body mass index \>35 Kg/m2. * Secondary causes of hypertension. * Grade 2 (moderate) or 3 (severe) hypertension: clinic blood pressure \>160/100 mm Hg. * Resistant hypertension: clinical blood pressure ≥140/90 mm Hg despite concurrent use of three antihypertensive agents of different classes, one of which is a diuretic. * Clinical systolic blood pressure \<100 mm Hg or history of symptomatic orthostatic hypotension. * Cardiovascular event, procedure, or hospitalization for unstable angina with the last 6 months. * Atrial fibrillation. * Heart failure. * Treatment with nitrates. * Estimated glomerular filtration rate (eGFR) \<45 mL/min. * Diagnosis of polycystic kidney disease. * Glomerulonephritis treated with or likely to be treated with immunosuppressant drugs * Uncontrolled diabetes with HbA1c \>9.0% (\>75 mmol/mol). * Uncontrolled dyslipidaemia with total serum cholesterol \>7.5 mmol/L or triglycerides \>5.6 mmol/L. * Clinical diagnosis of dementia, treatment with medications for dementia or, in the opinion of the study staff, the participant is cognitively unable to follow the protocol. * Other medical, psychiatric, or behavioural factors that in the judgment of the study staff may interfere with study participation. * Cancer diagnosed and treated within the past 2 years that, in the judgment of the study staff, would compromise a participant's ability to comply with the protocol and complete the study. * Any organ transplant. * Pregnancy, currently trying to become pregnant, or of child bearing potential and not using birth control. * Significant illness within 2 weeks of study start. * Patients with an unstable active medical condition that could impair evaluation of study results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in peripheral systolic blood pressure | Change from baseline peripheral systolic blood pressure at 6 months | Change in peripheral systolic blood pressure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in peripheral and central blood pressure | Change from baseline peripheral and central blood pressure at 6 months | Change in peripheral and central blood pressure |
| Change in arterial stiffness | Change from baseline pulse wave velocity at 6 months | Change in pulse wave velocity |
| Change in arterial wave reflection | Change from baseline augmentation index at 6 months | Change in augmentation index |
| Change in adenosine | Change from baseline adenosine concentrations at 6 months | Change in adenosine concentrations |
| Change in arginine metabolites | Change from baseline ADMA concentrations at 6 months | Change in ADMA concentrations |
Countries
Australia
Outcome results
None listed